BioMedNewsBreaks

TuesdaySep 02, 2025 12:30 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2025 Results and Strengthened Cash Position

Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, reflecting continued growth in its CDMO business. R&D expenses fell to $1.24 million from $2.79 million, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier. Cash and equivalents totaled $989,000 as of June 30, with an additional $4.2 million raised in July and August under the Company’s Standby Equity Purchase Agreement, significantly strengthening liquidity. Scinai advanced its anti-IL-17 NanoAb program,…

Continue Reading

TuesdaySep 02, 2025 11:43 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present at H.C. Wainwright Global Investment Conference 

Calidi Biotherapeutics (NYSE American: CLDI), announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting Sept. 5 at 7 a.m. ET, highlighting Calidi’s RedTail platform, which is designed to protect virus from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration. To view the full press release, visit https://ibn.fm/xkZw3 About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the…

Continue Reading

TuesdaySep 02, 2025 11:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event. To view the full press release, visit https://ibn.fm/J0aJi About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where…

Continue Reading

TuesdaySep 02, 2025 9:20 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference

Clene (NASDAQ: CLNN) announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings. To view the full press release, visit https://ibn.fm/d4eRn About Clene Inc. Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8(R)is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and…

Continue Reading

FridayAug 29, 2025 3:10 pm

BioMedNewsBreaks — Zevra Therapeutics, Inc. (NASDAQGS: ZVRA) to Present New MIPLYFFA Data at ICIEM, Poster Earns Best Poster Award

Zevra Therapeutics (NASDAQGS: ZVRA), a commercial-stage company focused on therapies for rare diseases, announced that four posters on MIPLYFFA (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), held Sept. 2-6, 2025, in Kyoto, Japan. MIPLYFFA, approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), will be highlighted in a Best Poster award-winning presentation (#BP-19) detailing its unique mechanism of action targeting NPC pathophysiology. Additional presentations will feature positive new data from a pediatric substudy in patients younger than two years old and a prespecified efficacy analysis in patients on miglustat…

Continue Reading

FridayAug 29, 2025 9:49 am

BioMedNewsBreaks — Propanc Biopharma, Inc. (NASDAQ: PPCB) Closes $4 Million Public Offering 

Propanc Biopharma (NASDAQ: PPCB) announced the closing of its underwritten public offering of 1,000,000 shares of common stock at $4.00 per share, generating $4 million in gross proceeds before deducting underwriting discounts and expenses. The Company also granted the underwriter a 45-day option to purchase up to 150,000 additional shares. The shares commenced trading on the Nasdaq Capital Market on Aug. 15, 2025, with the offering closing on Aug. 18, 2025. D. Boral Capital LLC and Craft Capital Management LLC acted as book running managers for the offering. To view the full press release, visit https://ibn.fm/QxpyL About Propanc Biopharma, Inc.…

Continue Reading

ThursdayAug 28, 2025 3:03 pm

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development

Lantern Pharma (NASDAQ: LTRN) recently unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). “The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development,” reads a recent article. “By embedding this technology into RADR(R), Lantern Pharma continues to position itself as a developer of data-driven approaches to oncology drug development. The module not only improves the chances of clinical success but also aligns with growing industry efforts to personalize cancer treatments based on molecular and genetic profiles.” To view the…

Continue Reading

ThursdayAug 28, 2025 2:37 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Showcases Pipeline and CEO’s Intellectual Property Legacy

Oncotelic Therapeutics (OTCQB: OTLC), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlighted its oncology pipeline and the extensive intellectual property contributions of Chairman and CEO Dr. Vuong Trieu, who holds more than 500 filed and 75 issued patents and co-developed blockbuster therapeutics Abraxane(R) and Cynviloq(TM). The Company’s portfolio includes OT-101 in Phase 3 for pancreatic cancer, OXi4503 advancing toward Phase 3 in AML/MDS, CA4P/Fosbretabulin in late-stage repositioning, AL-101 in Phase 2 for Parkinson’s and sexual dysfunctions, AL-102 in discovery for Alzheimer’s, and multiple pediatric rare disease programs with potential to generate Priority Review Vouchers, reinforcing…

Continue Reading

ThursdayAug 28, 2025 1:22 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Profiled on Credit-Card-Sized Device That Synthesizes 12-Lead ECG 

HeartBeam (NASDAQ: BEAT) is the focus of a piece by Susan Shepard for MD+DI detailing how the company’s credit-card-sized ECG device captures three-dimensional signals to synthesize a full 12-lead output. Cleared by the FDA last December, the portable system is designed for patients to carry in a wallet or purse for on-demand readings, providing hospital-level arrhythmia evaluation outside traditional settings. CEO Rob Eno explained that the device records up-down, side-to-side, and front-to-back signals, which the company’s algorithm then converts into a 12-lead ECG. HeartBeam expects FDA clearance for the algorithm later this year. The coverage also highlights HeartBeam’s partnership with…

Continue Reading

ThursdayAug 28, 2025 10:30 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at Three September Investor Conferences

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in September. At these events, the executives will meet with partners and investors while providing updates on the company’s commercialization progress, including demonstrations of its FDA-cleared HeartBeam System, a cable-free, credit card-sized device that collects 3D ECG signals for arrhythmia assessment. To view the full press release, visit https://ibn.fm/iTYHV About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology…

Continue Reading